LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Chembio Diagnostics Announces Two New Senior-Level Appointments

By LabMedica International staff writers
Posted on 25 Oct 2016
Image: New Chembio President Robert Passas, Ph.D (Photo courtesy of Chembio).
Image: New Chembio President Robert Passas, Ph.D (Photo courtesy of Chembio).
Chembio Diagnostics, Inc. (Medford, NY, USA), which develops, manufactures, licenses and markets rapid point-of-care (POC) diagnostic tests for infectious diseases, has made two new senior-level appointments.

Chembio has brought on board Robert Passas, Ph.D., as its President, EMEA and APAC regions, and promoted Sharon Klugewicz from the company’s Chief Operating Officer to President, Americas region. Dr. Passas will be responsible for the company’s commercial operations in Europe, Middle East, Africa, and Asia, while Ms. Klugewicz will be responsible for sales, marketing, customer support, clinical and regulatory affairs, and quality systems in the Americas. She will be tasked with leading the U.S. commercial team and expanding commercial operations throughout Latin America, the U.S. and Canada.

Dr. Passas, who holds a B.S. in medical biochemistry and a Ph.D. in analytical chemistry from the University of Surrey, U.K., has over 25 years of experience in general management and commercial operations in the field of clinical diagnostics. He has previously been with Abbott, Quidel, The Binding Site, and most recently Trinity Biotech, where he was responsible for worldwide marketing and international sales.

Chembio CEO John Sperzel commented, "We are delighted to add someone of Bob's caliber to our commercial leadership team at a time when our product portfolio is expanding beyond sexually transmitted disease, to include future POC tests for fever and tropical diseases such as Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa and Marburg. He has significant industry experience in commercial operations, having worked for several of the world's leading diagnostic companies, and a track record of building highly effective worldwide sales and marketing teams. We expect Bob to make an immediate impact by creating the framework for commercial success throughout the EMEA and APAC regions."

Ms. Klugewicz, who has received a B.S. in Neurobiology from Stony Brook University and a M.S. in Biochemistry from Adelphi University, joined Chembio in 2012 after working for 20 years at Pall Corporation, where she was Senior Vice President, Scientific and Laboratory Services.

Mr. Sperzel further commented, "Since joining Chembio, Sharon has established a track record of success in a number of areas, including manufacturing, product development, regulatory affairs, and quality systems. I've had the pleasure of working closely with her since 2014, and she has demonstrated the right combination of skills, knowledge and attributes to assume the leadership of commercial operations in the Americas region."

Related Links:
Chembio Diagnostics

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Laboratory Software
ArtelWare

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more